Facebook
Twitter
LinkedIn
ForwardWebcast of BTF’s ASH Annual Meeting Review 2023 - Portland
This accredited continuing education activity “Webcast of BTF’s ASH Annual Meeting Review 2023 - Portland”, is recorded from the live course held on 1/6-7/2023.
If you participated in the live course titled - BTF’s ASH Annual Meeting Review 2023 - Portland on 1/6-7/2023 and claimed CME credits/MOC points for that activity, you do not qualify for CME credits/MOC points for your participation in this enduring activity. This is a recorded content from that live course on 1/6-7/2023. However, you can still enroll in this activity and review the contents as needed.
The BTF’s ASH Annual Meeting Review 2023 - Portland was a CME-accredited, in-person hematology conference featuring leading experts in the field. This conference allowed professionals an opportunity to discuss current research and advances in the field of blood disorders and hematologic malignancies with colleagues and key opinion leaders. Expert faculty placed key abstract findings from the 64th American Society of Hematology (ASH) Annual Meeting into clinical context and discuss how the results may change the current standard of care. The goals of this conference were to review and critically assess practice-changing results of practice-changing clinical data and expert recommendations to optimize clinical outcomes for the patients.
This activity was planned and implemented by the Binaytara Foundation to educate hematologists/oncologists and others involved in the care of patients with hematologic malignancies and benign hematological disorders about the most important updates from the 64th American Society of Hematology (ASH) Annual Meeting in December 2022. Neither the Binaytara Foundation nor this activity is affiliated with the American Society of Hematology (ASH).
REGISTRATION FEES:
This activity is free for all healthcare providers who are not employees of an ineligible entity. Please select "non-industry learner" when you are ready to register for the course, and the price will reset to $0.
Healthcare providers ($0.00)
Industry employees ($200 + 3% Credit card fee)
If you are a healthcare provider involved in patient care and you are not employed by the Industry, then you don't pay anything to register for this activity.
If you are employed by industry, you must pay a registration fee to participate in these meetings. Any unpaid industry registrations will be invoiced $412 per participant.
If you paid to join the live meeting associated with this webcast and wish to register for this enduring material please contact us and we will register you for free.
Target Audience
- Hematologist/Oncologists
- Oncology Physician Assistants/Nurse Practitioners
- Oncology Pharmacists
- Oncology Nurses
Learning Objectives
Upon successful completion of this educational activity, participants will be able to:
- Review data presented at the 64th ASH Annual Meeting (2022) and discuss their application in clinical settings.
- Choose new therapeutic options for the treatment of blood disorders and hematologic malignancies, understanding appropriate indications, and contraindications to these therapeutic approaches.
- Discuss the study design and primary endpoints of recently reported and ongoing trials that have influenced the changes in the standards of care for patients with blood disorders and hematologic malignancies.
- Integrate evolving diagnostic, prognostic, and therapeutic approaches to the management of patients with blood disorders and hematologic malignancies.
- Apply practical expertise gained from clinical situations emphasizing data-based approaches to patients with blood disorders and hematologic malignancies in community practice.
This educational activity features recorded videos from the live webinar course titled - BTF’s ASH Annual Meeting Review 2023 - Portland held 1/6-7/2023.
The videos are placed in the following order. Feel free to view the content that is relevant to you.
Participants should claim continuing education credits to the extent of their participation.
Session 1
95 minutes - Tumor board style case-based discussion - Dr. Aaron Goodman, Dr. Sri Tantravahi, Dr. Natasha Edwin, Dr. Eva Medvedova, & Dr. Curtis Lachowiez
Session 2
35 minutes - Myelodysplastic Syndromes - Dr. Luke Fletcher
30 minutes - Myeloproliferative Neoplasms and CML - Dr. Vivian Oehler
35 minutes - Acute Leukemia - Dr. Roland Walter
Session 3
20 minutes - ITP/TTP, aHUS - Dr. George Rodgers
25 minutes - Clotting Disorders - Dr. Livia Hegerova
25 minutes - Bleeding Disorders - Dr. Joseph Shatzel
Session 4
35 minutes - Chronic Lymphocytic Leukemia - Dr. Mazyar Shadman
30 minutes - Low Grade Lymphomas - Dr. Ryan Lynch
30 minutes - Aggressive Lymphoma - Dr. Stephen Spurgeon
Session 5
30 minutes - Newly Diagnosed Multiple Myeloma - Dr. Shaji Kumar
35 minutes - Cellular Therapy - Dr. Rahul Banerjee
25 minutes - Relapsed Refractory Multiple Myeloma - Dr. Surbhi Sidana
IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:
All conflict of interest has been identified and mitigated for individuals in control of contents.
PLANNING COMMITTEE DISCLOSURE STATEMENT:
None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.
CHAIR
Srinivas Tantravahi, MD has a financial relationship (Consulting) with Novartis; a financial relationship (Consulting) with AbbVie; a financial relationship (Research support/Grant Consultant) with Karyopharm Therapeutics.
MODERATOR(S)
Hidong Kim, MD, PhD has no relevant financial relationships to disclose at this time.
Craig Okada has no relevant financial relationships to disclose at this time.
Bo Wang, MD has a financial relationship (Independent contractor) with EMD Sorono; financial relationship (Independent contractor) with Astra Zeneca; financial relationship (Independent contractor) with Sanofi Genzyme; financial relationship (Independent contractor) with Pfizer; financial relationship (Independent contractor) with Guardant .
SPEAKER(S)
Rahul Banerjee, MD, FACP has a financial relationship (Grant Or Contract) with Pack Health; financial relationship (Grant Or Contract) with Clinical Care Options; financial relationship (Independent contractor) with Guidepoint Global; financial relationship (Independent contractor) with Janssen Oncology; financial relationship (Grant Or Contract) with Curio Science; financial relationship (Independent contractor) with Sanofi Pasteur; financial relationship (Independent contractor) with Genentech/Roche; financial relationship (Independent contractor) with SparkCures; financial relationship (Independent contractor) with Clearview Healthcare Partners; financial relationship (Grant Or Contract) with i3 Health.
Natasha Edwin, MBBS MD has no relevant financial relationships to disclose at this time.
Luke Fletcher, MD has a financial relationship (Professional Services) with Blueprint; financial relationship (Gift) with Janssen; financial relationship (Professional Services) with Sanofi; financial relationship (Professional Services) with Novartis; financial relationship (Professional Services) with CARIS.
Aaron Goodman, MD has a financial relationship (Professional Services) with Seattle Genetics.
Livia Hegerova, MD has a financial relationship (Grant Or Contract) with Agios; financial relationship (Grant Or Contract) with Sanofi; financial relationship (Grant Or Contract) with Rigel.
Shaji Kumar, MD has a financial relationship (Professional Services) with Consulting/Advisory Board participation: (with no personal payments) Abbvie, Amgen, BMS, Janssen, Roche-Genentech, Takeda, Astra-Zeneca, Bluebird Bio, Epizyme, Secure Biotherapeutics and (with personal payment) Oncopeptides, Beigene, Antengene ; financial relationship (Grant Or Contract) with Research funding for clinical trials to the institution: Abbvie, Amgen, BMS, Carsgen, Janssen, Astra-Zeneca, Novartis, Roche-Genentech, Takeda, Tenebio, Molecular Templates.
Curtis Lachowiez, M.D. has no relevant financial relationships to disclose at this time.
Ryan Lynch, MD has a financial relationship (Grant Or Contract) with Juno Therapeutics; financial relationship (Grant Or Contract) with Genentech; financial relationship (Grant Or Contract) with TG Therapeutics; financial relationship (Grant Or Contract) with Cyteir; financial relationship (Grant Or Contract) with Bayer; financial relationship (Grant Or Contract) with Incyte; financial relationship (Other) with Morphosys; financial relationship (Grant Or Contract) with RAPT; financial relationship (Grant Or Contract) with SeaGen.
Eva Medvedova, MD has no relevant financial relationships to disclose at this time.
Vivian Oehler, MD has a financial relationship (Other) with Novartis; financial relationship (Grant Or Contract) with Pfizer, Inc.GEORGE RODGERS, MD, PhD has a financial relationship (Professional Services) with Dova; financial relationship (Professional Services) with Argenx.
Mazyar Shadman, MD,MPH has a financial relationship (Professional Services) with Mustang Bio; financial relationship (Professional Services) with AbbVie; financial relationship (Professional Services) with Genmab; financial relationship (Professional Services) with Genentech; financial relationship (Professional Services) with AstraZeneca; financial relationship (Professional Services) with Pharmacyclics; financial relationship (Professional Services) with BeiGene; financial relationship (Employment) with BMS; financial relationship (Professional Services) with BMS; financial relationship (Professional Services) with TG Therapeutics; financial relationship (Professional Services) with MorphoSys/Incyte.
Joseph Shatzel, MD has a financial relationship (Professional Services) with Aronora.
Surbhi Sidana, MD has a financial relationship (Professional Services) with Magenta Therapeutcs, BMS, Janssen, Sanofi, Oncopeptides; financial relationship (Grant Or Contract) with Magenta Therapeutics, BMS, Allogene, Janssen.
Stephen Spurgeon, MD has a financial relationship (Professional Services) with Janssen; financial relationship (Grant Or Contract) with Acerta; financial relationship (Professional Services) with Genentech; financial relationship (Grant Or Contract) with Beigene; financial relationship (Grant Or Contract) with BMS/Celgene; financial relationship (Other) with Schrodinger; financial relationship (Professional Services) with Astra Zeneca; financial relationship (Grant Or Contract) with Merck.
Roland Walter, MD PhD MS has no relevant financial relationships to disclose at this time.
Important Information about Claiming CME for this activity:
If you participated in the live course titled - BTF’s ASH Annual Meeting Review 2023 - Portland on 1/6-7/2023 and claimed CME credits/MOC points for that activity, you do not qualify for CME credits/MOC points for your participation in this enduring activity. This is a recorded content from that live course on 1/6-7/2023. However, you can still enroll in this activity and review the contents as needed.
Available Credit
- 7.50 ABIM MOC IISuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
- 7.50 AMA PRA Category 1 Credit™The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 7.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 7.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
- 7.50 Nursing Contact HoursProvider approved by the California Board of Registered Nursing, Provider # CEP17035, for 7.50 Contact Hours.
Price
REGISTRATION FEES:
This activity is $0 for all.
Cancellation Policy
You may cancel your enrollment at any time. No credits will be offered if you do not complete all required steps of this activity which include registration, watching the recorded content, and completion of pre & post tests as well as course evaluations.